Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women

Completed · Phase 3 · Has a placebo group

Conditions studied: Breast Cancer

In brief

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using raloxifene and tamoxifen may fight breast cancer by blocking the uptake of estrogen by the tumor cells. PURPOSE: Randomized double-blinded clinical trial to compare the effectiveness of raloxifene with that of tamoxifen in preventing breast cancer in postmenopausal women.

Key facts

Study ID
NCT00003906
Run by
NSABP Foundation Inc
People needed
19747
Starts
1999-05-01
Expected to finish
2012-08-01
Last updated by the study team
2015-10-06

Who can join

Age: 35 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.